David Johnson, Chairman and CEO of Enveric Biosciences, a biotechnology company developing cannabinoid medicines to treat cancer and who last joined the Green Rush in March, and Dr. Joseph Tucker, CEO of MagicMed, a psychedelics company focused on creating a library of novel psychedelic molecules to treat a variety of indications are this week’s special guests on The Green Rush.
At the end of May, Enveric and MagicMed announced they had entered into a definitive merger agreement that will combine the research and discovery elements of the two companies to study how psychedelics and cannabinoids can benefit patients’ bodies and minds.
Anne and Nick sat down with David and Joseph to discuss the transaction, including how the deal came together, how the deal will benefit both patients and investors and the potential these new generations of medicines hold for patients suffering from a variety of indications. They also touch on some of the biggest challenges facing these industries and what they hope to accomplish in the near and long-term
So don’t sit back, lean forward and enjoy our conversation with David Johnson and Dr. Joseph Tucker.
Links and mentions in the show
Links to the guest’s company and social media accounts
- David Johnson’s LinkedIn: https://www.linkedin.com/in/david-johnson-235b0224/
- MagicMed LinkedIn: https://www.linkedin.cn/company/magicmedind
This episode was hosted by Anne Donohoe and Nick Opich of KCSA Strategic Communications.
Special thanks to our Program Director Shea Gunther.
You can learn more about how KCSA Cannabis can help your cannabiz by visiting www.kcsa-cannabis.com or emailing firstname.lastname@example.org. You can also connect with us via our social channels: